<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03963921</url>
  </required_header>
  <id_info>
    <org_study_id>HEP201</org_study_id>
    <nct_id>NCT03963921</nct_id>
  </id_info>
  <brief_title>Safety and Tolerability of HepaStem in Patients With Cirrhotic and Pre-cirrhotic NASH Patients</brief_title>
  <acronym>PANASH</acronym>
  <official_title>Multicenter, Open-label, Safety and Tolerability Study of Ascending Doses of HepaStem in Patients With Cirrhotic and Pre-cirrhotic Non-alcoholic Steato-hepatitis (NASH)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Promethera Biosciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Promethera Biosciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multicenter, open-label, safety and tolerability study of ascending doses of HepaStem in&#xD;
      patients with cirrhotic and pre-cirrhotic non-alcoholic steato-hepatitis (NASH) to determine&#xD;
      the safety and tolerability of ascending single and repeated doses of HepaStem administered&#xD;
      to patients with cirrhotic and pre-cirrhotic non-alcoholic steato-hepatitis (NASH)&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 9, 2019</start_date>
  <completion_date type="Actual">August 31, 2020</completion_date>
  <primary_completion_date type="Actual">May 28, 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Adverse Event</measure>
    <time_frame>up to Day 28</time_frame>
    <description>Safety and Tolerability</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>NASH - Nonalcoholic Steatohepatitis</condition>
  <arm_group>
    <arm_group_label>F4 patient population</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A total of 2 doses are planned to be administered as single or repeated infusions in an ascending manner:</description>
  </arm_group>
  <arm_group>
    <arm_group_label>F3 patient population</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A total of 2 doses are planned to be administered as single or repeated infusions in an ascending manner:</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HepaStem</intervention_name>
    <description>Heterologous human adult liver-derived progenitor cells</description>
    <arm_group_label>F3 patient population</arm_group_label>
    <arm_group_label>F4 patient population</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria:&#xD;
&#xD;
          -  Able and willing to provide written informed consent and comply with the requirements&#xD;
             of this study protocol&#xD;
&#xD;
          -  Age 18 to 70-years old, inclusive&#xD;
&#xD;
          -  Proven diagnosis of NASH based on histological evidence from biopsy performed within 6&#xD;
             months for F3 patients and within 2 years for F4 patients prior to Screening If no&#xD;
             biopsy is available within these time windows, a biopsy should be performed at&#xD;
             Screening NB: For F4 patients for whom the biopsy cannot confirm the diagnosis of&#xD;
             NASH, any other causes of underlying liver diseases should be excluded&#xD;
&#xD;
        Main Exclusion Criteria:&#xD;
&#xD;
          -  Alcoholic liver disease or alcohol consumption exceeding the daily intake of 140g/w&#xD;
             (two doses) for women and of 210g/w (three doses) for men&#xD;
&#xD;
          -  Other causes of liver disease including, but not limited to, alcoholic liver disease,&#xD;
             active hepatitis B (HbsAg+), hepatitis C (PCR positive), autoimmune disorders,&#xD;
             drug-induced hepatotoxicity, Wilson disease, hemochromatosis, and alpha-1-antitryspin&#xD;
             deficiency based on medical history and/ or clinical and biological assessment&#xD;
&#xD;
          -  Recent recurrent or ongoing thrombotic or bleeding events within 3 months prior the&#xD;
             screening&#xD;
&#xD;
          -  Patients considered at persistent risk of thrombosis or bleeding at the time of&#xD;
             screening&#xD;
&#xD;
          -  Patients with high risk of Gastro intestinal bleeding at time of the screening.&#xD;
&#xD;
          -  Cerebrovascular, myocardial, or limb arterial thrombotic event within 12 months prior&#xD;
             to the screening and/or not considered stabilized by the investigator&#xD;
&#xD;
          -  Bariatric surgery within 1 year prior to the screening&#xD;
&#xD;
          -  Coagulation disturbances defined as (Drolz et al. 2016, Nadim et al. 2016, Stravitz et&#xD;
             al. 2018, Green et al. 2018): fibrinogen at &lt; 80 mg/dL and/or platelets at &lt; 40 x&#xD;
             10³/mm3&#xD;
&#xD;
          -  Severe hepatic encephalopathy (defined by West Haven grade &gt; 2)&#xD;
&#xD;
          -  Acute Decompensation of cirrhosis with Chronic Liver Failure Consortium Acute&#xD;
             Decompensation (CLIF-C AD) score &gt; 60&#xD;
&#xD;
          -  Acute on Chronic liver failure (ACLF) grade 1, 2 ,3&#xD;
&#xD;
          -  MELD score &gt; 20&#xD;
&#xD;
          -  Child Pugh score ≥ C&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Etienne SOKAL, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>CSMO</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cliniques Universitaires St Luc</name>
      <address>
        <city>Brussels</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CUB Erasme</name>
      <address>
        <city>Brussel</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Antwerp (UZA)</name>
      <address>
        <city>Edegem</city>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Gent</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Multiprofile Hospital for Active Treatment &quot;Tsaritsa Yoana - ISUL&quot;</name>
      <address>
        <city>Sofia</city>
        <zip>1527</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Multiprofile hospital for active treatment (MHAT) Sofia Military Medical Academy</name>
      <address>
        <city>Sofia</city>
        <zip>1606</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Trakia Park Hospital</name>
      <address>
        <city>Stara Zagora</city>
        <zip>6004</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Paul Brousse Hospital</name>
      <address>
        <city>Villejuif</city>
        <zip>94804</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Gregorio Marañon</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ramón y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Bulgaria</country>
    <country>France</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>May 23, 2019</study_first_submitted>
  <study_first_submitted_qc>May 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 28, 2019</study_first_posted>
  <last_update_submitted>October 13, 2020</last_update_submitted>
  <last_update_submitted_qc>October 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>NASH</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

